Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study: An analysis with considerations for future studies
Kiran Javaid, Cassidy Andruszka
Abstract
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Topics & Concepts
MedicineRandomized controlled trialIntervention (counseling)Clinical trialPsoriasisDermatologyFamily medicineInternal medicineNursingDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisContact Dermatitis and Allergies